Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsDividends payablesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PharmaCyte Biotech (PMCB) Preferred Stock Liabilities (2023 - 2026)

PharmaCyte Biotech (PMCB) has disclosed Preferred Stock Liabilities for 4 consecutive years, with $1000.0 as the latest value for Q1 2026.

  • Quarterly Preferred Stock Liabilities changed N/A to $1000.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $1000.0 through Jan 2026, changed N/A year-over-year, with the annual reading at $1000.0 for FY2024, N/A changed from the prior year.
  • Preferred Stock Liabilities for Q1 2026 was $1000.0 at PharmaCyte Biotech, down from $901996.0 in the prior quarter.
  • The five-year high for Preferred Stock Liabilities was $21.3 million in Q4 2023, with the low at $1000.0 in Q1 2024.
  • Average Preferred Stock Liabilities over 4 years is $4.3 million, with a median of $1000.0 recorded in 2024.
  • The sharpest move saw Preferred Stock Liabilities plummeted 100.0% in 2024, then skyrocketed 90099.6% in 2025.
  • Over 4 years, Preferred Stock Liabilities stood at $21.3 million in 2023, then tumbled by 100.0% to $1000.0 in 2024, then surged by 90099.6% to $901996.0 in 2025, then crashed by 99.89% to $1000.0 in 2026.
  • According to Business Quant data, Preferred Stock Liabilities over the past three periods came in at $1000.0, $901996.0, and $1000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.